Literature DB >> 8780546

Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate carcinoma?

V Ravery1, H P Schmid, M Toublanc, L Boccon-Gibod.   

Abstract

BACKGROUND: Information regarding the quantity of biopsy material invaded by cancer may supplement the usual criteria for the preoperative staging of patients suffering from clinically localized prostate carcinoma (T1-T2). However, conflicting conclusions have been drawn and this topic needs further investigation.
METHODS: A total of 170 patients had radical prostatectomy for T1-T2 prostate carcinoma. Patients' mean age (+/- standard deviation [SD]) was 66.05 +/- 6.12 years and mean prostate specific antigen (PSA) level (+/- SD) was 22.5 +/- 21.4 ng/mL (Yang Proscheck). Of the patients, 110 underwent transrectal ultrasound-guided biopsy with removal of 6 cores, from whom we had the percentage of biopsy, material invaded by cancer, the Gleason score, and the preoperative PSA. These parameters were compared with the pathologic features of the surgical specimen (capsule penetration, surgical margins, and Gleason score) and biologic progression (defined as persistent/recurrent postoperative PSA > 0.1 ng/mL).
RESULTS: The most valid threshold of biopsy material invaded by cancer for predicting surgical margins and capsule status, as well as biologic progression, was 10%. When < 10% of biopsy material was invaded by cancer, positive surgical margins (SM+) were present in 30.3%, capsular penetration (pT3, pathologic extracapsular involvement) in 27.3%, and biologic progression (P+) in 21.7%. The Gleason score did not improve this prognostic evaluation. The mean quantities of tissue invaded by cancer differed significantly between positive and negative surgical margin groups, between pT2 and pT3 groups, and between P- and P+ groups (no biologic progression/biologic progression). There was statistical significance (log rank test, P = 0.0320 in the survival without biologic postoperative progression between patients with < or = or > 10% of one core biopsy invaded by tumor. If < or = 10% of tissue in only 1 of 6 cores of a biopsy was invaded by tumor, the status was pT2, SM-, and P- in 87.5% of the patients.
CONCLUSIONS: On an individual basis, the percent of tissue containing carcinoma in core biopsies was a factor that lacked the statistical power to predict the status of the capsule and surgical margins, and the biologic progression. The finding of < or = 10% of carcinoma in 1 of 6 cores of a biopsy was correlated with a good prognosis.

Entities:  

Mesh:

Year:  1996        PMID: 8780546     DOI: 10.1002/(SICI)1097-0142(19960901)78:5<1079::AID-CNCR18>3.0.CO;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Pre-operative prediction of advanced prostatic cancer using clinical decision support systems: accuracy comparison between support vector machine and artificial neural network.

Authors:  Sang Youn Kim; Sung Kyoung Moon; Dae Chul Jung; Sung Il Hwang; Chang Kyu Sung; Jeong Yeon Cho; Seung Hyup Kim; Jiwon Lee; Hak Jong Lee
Journal:  Korean J Radiol       Date:  2011-08-24       Impact factor: 3.500

2.  A review of surgical techniques for radical prostatectomy.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2005

3.  Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort.

Authors:  Ramzi Rajab; Gabrielle Fisher; Michael W Kattan; Christopher S Foster; Tim Oliver; Henrik Møller; Victor Reuter; Peter Scardino; Jack Cuzick; Daniel M Berney
Journal:  Virchows Arch       Date:  2010-09-09       Impact factor: 4.064

4.  High-grade prostatic adenocarcinoma present in a single biopsy core is associated with increased extraprostatic extension, seminal vesicle invasion, and positive surgical margins at prostatectomy.

Authors:  Alcides Chaux; Daniel A Fajardo; Nilda Gonzalez-Roibon; Alan W Partin; Mario Eisenberger; Theodore L DeWeese; George J Netto
Journal:  Urology       Date:  2011-12-14       Impact factor: 2.649

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.